PharmaCyte Biotech
PMCB
29 hedge funds and large institutions have $2.32M invested in PharmaCyte Biotech in 2024 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 8 increasing their positions, 10 reducing their positions, and 4 closing their positions.
6,200% more call options, than puts
Call options by funds: $63K | Put options by funds: $1K
1% less capital invested
Capital invested by funds: $2.35M → $2.32M (-$28.6K)
1.08% less ownership
Funds ownership: 12.63% → 11.55% (-1.1%)
9% less funds holding
Funds holding: 32 → 29 (-3)
20% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 10
75% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KPF
K2 Principal Fund
Toronto,
Ontario, Canada
|
+$49.5K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$41.5K |
| 3 |
Renaissance Technologies
New York
|
+$12.3K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$7.07K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$2.93K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$178K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$43.4K |
| 3 |
Bank of New York Mellon
New York
|
-$35.9K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
-$33.2K |
| 5 |
Squarepoint
New York
|
-$32.1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
BL
26
BFSG LLC
Irvine,
California
| $17 | +$15 | +7 | New |
|
27
Morgan Stanley
New York
| $9 | -$11 | -5 | -63% |
|
|
NA
28
NewEdge Advisors
New Orleans,
Louisiana
| $7 | – | – | – |
|
|
SM
29
Sabby Management
Miami Beach,
Florida
| – | -$178K | -82,373 | Closed |
|
|
30
Bank of New York Mellon
New York
| – | -$35.9K | -16,598 | Closed |
|
|
31
Squarepoint
New York
| – | -$32.1K | -14,846 | Closed |
|
32
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$236 | -109 | -41% |
|
33
Northwestern Mutual Wealth Management
Milwaukee,
Wisconsin
| – | -$30 | -14 | Closed |
|
PMCB Hedge Fund Activity: Q1 2024 in Review
29 of the 6,946 institutional investors tracked by Wall St. Rank reported a position in PharmaCyte Biotech (PMCB) for Q1 2024, worth a combined $2.32M — down 1.2% from $2.35M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of PMCB and 1 opened new positions — a net loss of 3 holders — while 10 trimmed existing stakes and 8 added.
The largest buyer was K2 Principal Fund, adding an estimated $49.5K. The largest seller was Sabby Management, exiting entirely with an estimated $178K sold.
- 29 institutional investors held PharmaCyte Biotech (PMCB) as of Q1 2024, down from 32 in Q4 2023.
- Funds reported $2.32M of PharmaCyte Biotech stock for Q1 2024, down 1.2% quarter-over-quarter.
- 1 fund opened new PharmaCyte Biotech positions in Q1 2024 and 4 closed out, a net change of -3 holders.
- The largest PharmaCyte Biotech buyer in Q1 2024 was K2 Principal Fund, an estimated $49.5K added.
- The largest PharmaCyte Biotech seller in Q1 2024 was Sabby Management, an estimated $178K sold.
Based on aggregated 13F filings for Q1 2024.